SINUS-52

Patients experienced relief of symptoms and improvement in quality of life, as measured by SNOT-22, as follows:

• Week 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -10.57 (95% CI: -14.47, -6.66) (-18.97 from a baseline score of 50.16 vs -8.40 from a baseline score of 53.48, respectively)^4,a
• Week 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -16.76 (95% CI: -20.85, -12.67) (-27.08 from a baseline score of 50.16 vs -10.32 from a baseline score of 53.48, respectively)^4,a
• Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -20.96 (95% CI: -25.03, -16.89) (-29.84 from a baseline score of 50.16 vs -8.88 from a baseline score of 53.48, respectively)^4,a

^a22-item Sino-Nasal Outcome Test (SNOT-22) score (range 0 to 110): reduced score indicates improvement.¹

The SNOT-22 score is calculated from a patient questionnaire where 22 symptoms are rated from 0 (“no problem”) to 5 (“as bad is it can be”) based on the severity and frequency of each particular item.⁴

CI, confidence interval; CRSwNP, chronic rhinosinusitis with nasal polyposis; INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

See more about how DUPIXENT can improve symptoms & quality of life